Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 13;10(9):e038836.
doi: 10.1136/bmjopen-2020-038836.

Beta-alanine supplementation in patients with COPD receiving non-linear periodised exercise training or neuromuscular electrical stimulation: protocol of two randomised, double-blind, placebo-controlled trials

Roy Meys  1   2   3 , Anouk A F Stoffels  4   2   3   5 , Jana de Brandt  6 , Hieronymus W H van Hees  5 , Frits M E Franssen  4   2   3 , Maurice J H Sillen  7 , Emiel F M Wouters  4   2   3 , Chris Burtin  6 , Peter Klijn  8   9 , Eline Bij de Vaate  8 , Bram van den Borst  5 , Jacqueline M Otker  10   11 , Jos Donkers  11 , Florence N Schleich  12 , Maurice Hayot  13 , Pascal Pomiès  13 , Inge Everaert  14 , Wim Derave  14 , Martijn A Spruit  4   2   3   6 ; BASES consortium.
Affiliations

Beta-alanine supplementation in patients with COPD receiving non-linear periodised exercise training or neuromuscular electrical stimulation: protocol of two randomised, double-blind, placebo-controlled trials

Roy Meys et al. BMJ Open. .

Abstract

Introduction: Exercise intolerance is common in patients with chronic obstructive pulmonary disease (COPD) and, although multifactorial, it is largely caused by lower-limb muscle dysfunction. Research has shown that patients with severe to very severe COPD have significantly lower levels of muscle carnosine, which acts as a pH buffer and antioxidant. Beta-alanine (BA) supplementation has been shown to consistently elevate muscle carnosine in a variety of populations and may therefore improve exercise tolerance and lower-limb muscle function. The primary objective of the current studies is to assess the beneficial effects of BA supplementation in enhancing exercise tolerance on top of two types of exercise training (non-linear periodised exercise (NLPE) training or neuromuscular electrical stimulation (NMES)) in patients with COPD.

Methods and analysis: Two randomised, double-blind, placebo-controlled trials have been designed. Patients will routinely receive either NLPE (BASE-TRAIN trial) or NMES (BASE-ELECTRIC trial) as part of standard exercise-based care during their 8-to-10 week pulmonary rehabilitation (PR) programme. A total of 222 patients with COPD (2×77 = 154 patients in the BASE-TRAIN trial and 2×34 = 68 patients in the BASE-ELECTRIC trial) will be recruited from two specialised PR centres in The Netherlands. For study purposes, patients will receive 3.2 g of oral BA supplementation or placebo per day. Exercise tolerance is the primary outcome, which will be assessed using the endurance shuttle walk test (BASE-TRAIN) or the constant work rate cycle test (BASE-ELECTRIC). Furthermore, quadriceps muscle strength and endurance, cognitive function, carnosine levels (in muscle), BA levels (in blood and muscle), markers of oxidative stress and inflammation (in blood, muscles and lungs), physical activity and quality of life will be measured.

Ethics and dissemination: Both trials were approved by CMO Regio Arnhem-Nijmegen, The Netherlands (NL70781.091.19. and NL68757.091.19).

Trial registration number: NTR8427 (BASE-TRAIN) and NTR8419 (BASE-ELECTRIC).

Keywords: chronic airways disease; nutrition & dietetics; rehabilitation medicine; respiratory medicine (see thoracic medicine).

PubMed Disclaimer

Conflict of interest statement

Competing interests: FMEF reports research grants from AstraZeneca and Novartis, not related to the current projects, and personal fees for consultancies and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and TEVA. EBdV reports personal fees for consultancies and lectures from Boehringer Ingelheim, Chiesi, Mylan, Novartis, Vivisol and TEVA, not related to the current projects. FNS reports speakers fees from AstraZeneca, Chiesi, Menarini, Mundipharma and Novartis; reports consultancy fees from GSK; and reports service on an advisory board for AstraZeneca, Chiesi, GSK and Novartis, all outside the submitted work. MH reports research grants from Bastide Medical, not related to the current project; personal fees from AstraZeneca for participation to scientific lectures; financial support for congress participation from SOS Oxygène, Eole Santé, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca; and hospitalities during local scientific meetings from ALK-Abelló, Actelion Pharmaceuticals France, Vifor Fresenius Medical Care Renal Pharma, Sanofi Aventis France, Novartis Pharma, LVL Medical Sud, Chiesi, SOS Oxygene Mediterranee. MAS reports a research grant from Netherlands Lung Foundation (grant number 5.1.18.232) for the described BASE-TRAIN and BASE-ELECTRIC study. Moreover, MAS reports other grants from Netherlands Lung Foundation, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, and a grant from Stichting Astma Bestrijding, all outside the submitted work.

Figures

Figure 1
Figure 1
Timeline for the BASE-TRAIN trial, in which all measurements, inclusion criteria, moment of randomisation and supplementation period are outlined. AE, acute exacerbations; BA, beta-alanine; COPD, chronic obstructive pulmonary disease; ESWT, endurance shuttle walk test; FV, flow volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; NLPE, non-linear periodised exercise training; PL, placebo; PR, pulmonary rehabilitation.
Figure 2
Figure 2
Timeline for the BASE-ELECTRIC trial, in which all measurements, inclusion criteria, moment of randomisation and supplementation period are outlined. AE, acute exacerbations; BA, beta-alanine; CET, cycle endurance time; COPD, chronic obstructive pulmonary disease; CWRT, constant work rate cycle test; FV, flow volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; NMES, neuromuscular electrical stimulation; PL, placebo; PR, pulmonary rehabilitation; QMS, quadriceps muscle strength.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maltais F, Decramer M, Casaburi R, et al. . An official American thoracic Society/European respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:e15–62. 10.1164/rccm.201402-0373ST - DOI - PMC - PubMed
    1. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American thoracic Society and European respiratory Society. Am J Respir Crit Care Med 1999;159:S1–40. 10.1164/ajrccm.159.supplement_1.99titlepage - DOI - PubMed
    1. Spruit MA, Singh SJ, Garvey C, et al. . An official American thoracic Society/European respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13–64. 10.1164/rccm.201309-1634ST - DOI - PubMed
    1. O'Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. Chest 2009;136:1269–83. 10.1378/chest.09-0029 - DOI - PubMed
    1. Klijn P, van Keimpema A, Legemaat M, et al. . Nonlinear exercise training in advanced chronic obstructive pulmonary disease is superior to traditional exercise training. A randomized trial. Am J Respir Crit Care Med 2013;188:193–200. 10.1164/rccm.201210-1829OC - DOI - PubMed

Publication types